BIIB

#421
Biogen Inc. - Common Stock
196.0 0 USD
-0.74%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
196.00
196.06
Range Annuel
121.06
205.97
Changement quotidien
-0.74%
Changement Mensuel
+1.01%
Evolution sur 6 mois
+8.80%
Changement Annuel
+48.70%
Clôture Précédente
197.4 7
Open
196.0 6
Low
196.0 0
High
196.0 6
Volume
265
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur 202020212022202320242025

Biogen Inc. - Common Stock

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Nouvelles